The Small Animal Cancer Imaging Research Facility (SACIRF) provides cancer investigators with the latest technology and techniques for experimental in vivo imaging of small animals. The facility includes state-ofthe- art instrumentation, including the modalities of magnetic resonance (MR, Bruker4.7 T, 40 cm Biospec), x-ray computed tomography (micro-CT from Enhanced Vision Systems and volume CT being developed in collaboration with General Electric), projection radiography (Faxitron), and nuclear imaging (M.Cam gamma camera from Siemens and micro-PET from Concorde Microsystems). Optical imaging will be added during the first year of the award (instrumentation to be developed in collaboration with Biomedical Engineering at The University of Texas-Austin). This instrumentation represents a >$3M investment by MDACC. The SACIRF has allocated space for the instruments in the animal support facilities to facilitate the inclusion of the imaging studies in ongoing cancer research, and dedicated office and developmental laboratory space to support the facility operation. The faculty and staff are well-qualified in each of the modality areas, including current image acquisition and image analysis techniques. Specialty areas include quantitative tissue characterization (MR), imaging of microvascular physiology (MR, nuclear, CT and optical), diffusion imaging for estimating cellular density (MR), metabolic imaging (nuclear, positron emission tomography [PET], optical and MR spectroscopy), and vascular imaging (MR, CT, and x-ray). The services of the facility include imaging protocol design, custom positioning systems, custom data acquisition hardware and software, image analysis, data archiving, provision of hardcopy and digital data delivery, and database maintenance. The Veterinary Core includes a dedicated support team that provides highly efficient imaging studies and a very low mortality rate of animals during the imaging procedures. Services provided from the Veterinary Core include development of veterinary support protocols specific to each experimental design, and consultation on the inclusion of imaging procedures into existing protocols to obtain Institutional Animal Care and Use Committee approval. To date, 75 investigators representing 13 programs have used facility instrumentation. 42% of the users are peer-review-funded investigators. Utilization continues to increase as the facility and its capabilities become better known to the local cancer research community. The capabilities of the facility continue to grow to meet experimental demands. Publications are evolving at a rapid pace, and although only a few are published, the acceptance rate has been nearly 100%. Funding for the SACIRF is currently CCSG (43%), user fees (36%), and MDACC (21%).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-34
Application #
7928889
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
34
Fiscal Year
2009
Total Cost
$254,068
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Tanco, Kimberson; Azhar, Ahsan; Rhondali, Wadih et al. (2018) The Effect of Message Content and Clinical Outcome on Patients' Perception of Physician Compassion: A Randomized Controlled Trial. Oncologist 23:375-382
Elimova, Elena; Wang, Xuemei; Qiao, Wei et al. (2018) Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94:345-353
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6
Ma, Jiacheng; Huo, XiaoJiao; Jarpe, Matthew B et al. (2018) Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment. Acta Neuropathol Commun 6:103
Meisel, Jane; Zhang, Chao; Neely, Cameron et al. (2018) Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clin Breast Cancer 18:347-352
Williams, Patrick; Basu, Sreyashi; Garcia-Manero, Guillermo et al. (2018) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer :
Koyyalagunta, Dhanalakshmi; Bruera, Eduardo; Engle, Mitchell P et al. (2018) Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain. Pain Med 19:1469-1477
Liao, Zhongxing; Lee, J Jack; Komaki, Ritsuko et al. (2018) Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 36:1813-1822
Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2018) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res 27:2093-2113

Showing the most recent 10 out of 12418 publications